The outlook for Bristol-Myers Squibb (BMY) is for some steady growth. The
consensus of analysts is that earnings per share of $1.93 in the most recent
fiscal year will advance to $1.93 in the current year and then grow to $2.20
next year. With a return on equity of 25.8% and priced at only 10.6 times this
year’s estimated net income and 9.3 times next year’s predicted net, it
seems attractively prices, especially with a dividend yield of more than 6%.

TheStreet.com Ratings quantitative evaluation model assigns BMY a “reward
grade” of B-plus, a “risk grade” of C-minus and an “overall grade” of
B-minus, which equates with a “buy” recommendation.

Despite what some pundits are predicting, Big Pharma isn’t about to shrivel up
and die.

FDA says their Diabetes drug appears to be safe.